Does Adherence to Domiciliary NIMV Decrease the Subsequent Hospitalizations Rates and Cost for Patients Diagnosed with COPD?. (4th May 2018)

• Record Type: Journal Article
• Authors: Satici, Celal; Arpinar Yigitbas, Burcu; Seker, Baris; Demirkol, Mustafa Asim; Kosar, Ayse Filiz
• Is Part Of: COPD. Volume 15:Number 3(2018)
• Page Start: 303
• Page End: 309
• Publication Date: 2018-05-04
• Subjects: Chronic obstructive pulmonary disease -- noninvasive mechanical ventilation -- adherence -- length of stay -- hospital costs -- hospitalization; Lungs -- Diseases, Obstructive -- Periodicals; 616.24
• DOI: 10.1080/15412555.2018.1500532
• Languages: English
• ISSNs: 1541-2555

Abstract

Abstract: Domiciliary noninvasive mechanical ventilation (NIMV) is used for treating patients with hypercapnic chronic obstructive pulmonary disease (COPD). We aimed to evaluate the association between adherence to the treatment and subsequent hospitalizations and costs. Data from 54 (27 adherent; 27 non-adherent) patients with COPD who were undergoing NIMV treatment at home for 6 months. We assessed adherence based on digitally recorded data and checked hospital records for clinical and laboratory data, rehospitalization rates, and costs during the following 6 months. Nocturnal NIMV usage, mean daily usage of the device, and time to first hospitalization were higher in the treatment-adherent group ( p < .001, p < .001, and p =.006, respectively). The percentage of active smokers, device leaks above 30 L/min, length of hospital stay, rehospitalization rates, and costs were significantly higher in the treatment-non-adherent group ( p = 05, p = 006, p = 004, p = 006, and p = 01, respectively). The most frequent reasons for not using NIMV in the treatment-non-adherent group were a decreased need, dry mouth, mask incompatibility, and gastrointestinal complaints. Adherence to NIMV treatment decreases the subsequent hospitalizations rates and noncompliance leads to complications. Findings of this study may help physicians in convincing patients diagnosed with COPD of the need for correct NIMV use to prevent hospitalizations and reduce the costs of COPD treatment.